Egalet Corp. (NASDAQ:EGLT) shares were up 3.8% on Monday . The company traded as high as $8.38 and last traded at $8.27, with a volume of 84,356 shares. The stock had previously closed at $7.97.

EGLT has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $21.00 price objective on Egalet Corp. and gave the stock a “buy” rating in a report on Saturday, August 6th. Zacks Investment Research downgraded Egalet Corp. from a “hold” rating to a “sell” rating in a report on Thursday, May 12th.

The company has a 50 day moving average price of $6.93 and a 200-day moving average price of $6.58. The stock’s market capitalization is $203.71 million.

Egalet Corp. (NASDAQ:EGLT) last posted its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.82) by $0.15. The company had revenue of $3.45 million for the quarter, compared to analyst estimates of $3.83 million. During the same quarter in the previous year, the company earned ($1.03) EPS. Egalet Corp.’s revenue for the quarter was up 259.4% on a year-over-year basis. Analysts predict that Egalet Corp. will post ($3.47) earnings per share for the current year.

In other Egalet Corp. news, CEO Robert S. Radie sold 5,000 shares of Egalet Corp. stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $5.07, for a total value of $25,350.00. Following the transaction, the chief executive officer now owns 259,900 shares in the company, valued at $1,317,693. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Stan Musial sold 13,480 shares of Egalet Corp. stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $5.06, for a total transaction of $68,208.80. Following the completion of the transaction, the chief financial officer now owns 84,940 shares in the company, valued at approximately $429,796.40. The disclosure for this sale can be found here.

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.